all report title image
  • Published On : Dec 2022
  • Code : CMI1173
  • Industry : Pharmaceutical
  • Pages : 187
  • Formats :

Dry eye syndrome can be present in people with autoimmune diseases or other systemic conditions such as diabetes mellitus, Parkinson’s disease, rosacea, rheumatoid arthritis, systemic lupus erythematous, sarcoidosis, Sjögren syndrome, and thyroid disease. Moreover, problems associated with inflammation of the eyelids (blepharitis) or surfaces of the eye can lead to development of dry eyes. Furthermore, certain medications such as antihistamines, antidepressants, decongestants, and blood pressure medications can reduce tear production leading to dry eye symptoms. People who frequently use computer or screens are also at high risk of developing dry eyes, as using screens for a long period can lead to reduced blinking and tear production. Digital device usage has increased significantly in recent years among all age groups, due to extensive use for social and professional purposes.

Global dry eye syndrome market is estimated to be valued at US$ 7,245.3 million in 2022 and is expected to exhibit a CAGR of 16.4% during the forecast period (2022-2030).

Figure 1.Global Dry Eye Syndrome Treatment Market Share (%), by Product Type, 2022

Dry Eye Syndrome Treatment  | Coherent Market Insights

Global Dry Eye Syndrome Treatment Market - Drivers

Increasing organic strategies such as the U.S. Food and Drug Administration approval is expected to propel growth of the global dry eye syndrome treatment market during the forecast period. For instance, in October, 2022, Novaliq, a biopharmaceutical company focusing on ocular therapeutics, announce the approval of New Drug Application (NDA) by the U.S. Food and Drug Administration (FDA) for CyclASol (cyclosporine ophthalmic solution), an anti-inflammatory product for the treatment for the signs and symptoms of dry eye disease (DED).

Furthermore, key companies focusing on product launch of dry eye syndrome treatment are expected to propel growth of the global dry eye syndrome treatment market during the forecast period. For instance, in January 2022, Sun Pharmaceutical Industries, Inc., one of the global specialty generic pharmaceutical company, announced the launch of CEQUA (cyclosporine ophthalmic solution 0.09% w/v), a calcineurin inhibitor immunomodulator indicated to increase tear production in patients with moderate to severe keratoconjunctivitissicca (dry eye).

CMI table icon

Dry Eye Syndrome Treatment Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 7,245.3 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 16.4% 2030 Value Projection: US$ 24,449.7 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Product Type: Cyclosporine, Oral Corticosteroid, Artificial Tears, Omega Supplements, Punctual Bags, Others 
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Supermarket/ Hypermarket, Other Stores, Online Pharmacies 
Companies covered:

AbbVie Inc., Novartis AG, Bausch Health Companies Inc., Johnson & Johnson, Inc., I-MED Pharma inc., Santen Pharmaceutical Co., Ltd, AFT Pharmaceuticals, Novaliq GmbH, Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries, Inc., Teva Pharmaceutical Industries Ltd., Mitotech, SA, Viatris Inc.

Growth Drivers:
  • Increasing prevalence of dry eye syndrome 
  • Increasing research and development activities like clinical trials
Restraints & Challenges:
  • Lack of awareness of dry eye syndrome in emerging countries

Figure 2.Global Dry Eye Syndrome Treatment Market Share (%), by Region, 2022

Dry Eye Syndrome Treatment  | Coherent Market Insights

Global Dry Eye Syndrome Treatment– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 has affected the economy in three main ways: by directly affecting production and demand of drugs and vaccines, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, faced problems with regard to the transportation of drugs and vaccines from one place to another. Following the outbreak of COVID-19 in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization declared it a public health emergency. According to the World Health Organization’s report, manifestation of coronavirus (COVID-19) has resulted in more than 636,440,663 confirmed cases infected by COVID-19 worldwide as of 25 November, 2022.

Furthermore, COVID-19 pandemic has a significance impact on amputation due to increase in prevalence of dry eye syndrome. For instance, in June 2022, a research paper was published by Association for Research in Vision and Ophthalmology, a foundation for eye Research providing mentorship, has done Ocular Surface Disease Index (OSDI) survey according to which the prevalence rate of dry eye syndrome during COVID is high due to the wearing the mask, the use of electronic devices and working remotely during COVID- 19 pandemic. The low dry eye syndrome, moderate dry eye syndrome, and severe dry eye syndrome had a prevalence rate of 15%, 77.5 %, and 7.5 %, respectively in the year 2021.

Global Dry Eye Syndrome Treatment Market: Key Developments

In February 2021, Mitotech, SA, a Luxembourg-based single-molecule biotechnology company, in collaboration with Essex Bio-Technology Limited, a bio-pharmaceutical company announce the result of phase 3 clinical study of SkQ1 as a treatment for Dry Eye Disease (DED).The clinical study clearly indicate significant impact of SkQ1on central corneal staining, that is further supported by improvement in visual function to patients suffering from dry eye.

In August 2021, AFT Pharmaceuticals, a specialty pharmaceutical company, provided a clinical study data according to which NovaTears+Omega-3, indicated for dry eye treatment, shows significantly effective treatment for evaporative Dry Eye Disease.  The Meibomian Gland Assessment (MGD) score was taken which was improved from an entry level score of 7.1 to 3.0 (p<0.0001) over the course of the study. The latter result supports the hypothesis that the treatment might liquify meibum secretion excreted from the meibomian glands.

Global Dry Eye Syndrome Treatment Market: Restraint

The major factors that hinder growth of the global dry eye syndrome treatment include the lack of awareness of dry eye syndrome in emerging country such as Saudi Arabia. For instance in January 2021, a research article was published by International Journal of Medicine in Developing Countries, according to which a there is lack of awareness of dry eye syndrome among the Saudi Arabian population most of the people did not have routine ophthalmologist visits and tended

to use electronic devices for a long time without a break knowing the risk infecting with dry eye syndrome.

Global Dry Eye Syndrome Treatment market- Key Players

Major players operating in the global dry eye syndrome treatment include AbbVie Inc., Novartis AG, Bausch Health Companies Inc., Johnson & Johnson, Inc., I-MED Pharma inc., Santen Pharmaceutical Co., Ltd, AFT Pharmaceuticals, Novaliq GmbH, Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries, Inc., Teva Pharmaceutical Industries Ltd., Mitotech, SA, Viatris Inc., among other prominent players

Dry eye syndrome (DES) is also known as keratisis sicca and keratoconjunctivitis sicca. Dry eye disease is a common condition that occurs when your tears aren't able to provide adequate lubrication for your eyes. Patients suffering from DES show damage to the ocular surface, instability in the tear film, and visual disturbance. Tear film covers the ocular surface which is made up of three intertwined layers, a superficial lipid layer produced by meibomian glands assist in reducing tear evaporation and uniform tear spreading, middle thick aqueous layer produced from lacrimal glands, and the innermost hydrophilic mucin layer produced from goblet cells of conjunctiva and epithelium of ocular surface. Dry eye syndrome is associated with a long list of causes which can be divided into primary and secondary. Dry eye may develop secondary to inflammatory disease (e.g. vascular, allergic), environmental conditions (e.g. allergens, cigarette smoke, dry climate), hormonal imbalance (e.g. perimenopausal women and patients under hormone replacement therapy), and contact lens wear. Other causes of dry eye are certain diseases, such as rheumatoid arthritis, Sjögren’s syndrome, thyroid disease, and lupus Blepharitis (when eyelids are swollen or red), Entropion (when eyelids turn in), ectropion (eyelids turn outward) and being in smoke, wind or a very dry climate.

Market Dynamics

New dry eye therapies are introduced in the market with several new medications in the pipeline seeking approval. Strong product pipeline offers great market growth opportunity as approval of numerous pipeline products is expected to drive the market growth during the forecast period. For instance, in October 2021, Oyster Point Pharma, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of therapies to address ophthalmic disease, announce the U.S. Food and Drug Administration (FDA) approval for TYRVAYA (varenicline solution) Nasal Spray 0.03 mg, for the treatment of the signs and symptoms of dry eye disease. YRVAYA Nasal Spray is a selective cholinergic agonist delivered twice daily as an aqueous nasal spray into each nostril to activate basal tear production.

Key features of the study:

  • This report provides in-depth analysis of the global dry eye syndrome treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global dry eye syndrome treatment market  based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include AbbVie Inc., Novartis AG, Bausch Health Companies Inc., Johnson & Johnson, Inc., I-MED Pharma inc., Santen Pharmaceutical Co., Ltd, AFT Pharmaceuticals, Novaliq GmbH, Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries, Inc., Teva Pharmaceutical Industries Ltd., Mitotech, SA, Viatris Inc., among other prominent players
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global dry eye syndrome treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dry eye syndrome treatment market

Detailed Segmentation:

  • Global Dry Eye Syndrome Treatment Market, By Product Type:
    • Cyclosporine
    • Oral Corticosteroid
    • Artificial Tears
    • Omega Supplements
    • Punctual Bags
    • Others
  • Global Dry Eye Syndrome Treatment Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Supermarket/ Hypermarket
    • Other Stores
    • Online Pharmacies
  • Global Dry Eye Syndrome Treatment Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • AbbVie Inc.
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Novartis AG
    • Bausch Health Companies Inc.
    • Johnson & Johnson, Inc.
    • I-MED Pharma inc.
    • Santen Pharmaceutical Co., Ltd
    • AFT Pharmaceuticals
    • Novaliq GmbH
    • Otsuka Pharmaceutical Co., Ltd.
    • Sun Pharmaceutical Industries, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • Mitotech, SA
    • Viatris Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

Global dry eye syndrome treatment market size is estimated to be valued at US$ 7,245.3 million in 2022 and is expected to exhibit a CAGR of 16.4% between 2022 and 2030.
Increasing prevalence of dry eye syndrome and increasing research and development activities like clinical trials by the key players are driving growth of the market.
 Cyclosporine segment is the leading product type segment in the market.
The major factors hampering growth of the market include poor awareness of dry eye syndrome in emerging countries.
Major players operating in the include AbbVie Inc., Novartis AG, Bausch Health Companies Inc., Johnson & Johnson, Inc., I-MED Pharma inc., Santen Pharmaceutical Co., Ltd, AFT Pharmaceuticals, Novaliq GmbH, Otsuka Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries, Inc., Teva Pharmaceutical Industries Ltd., Mitotech, SA, Viatris Inc., among other prominent players

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo